Payment overview · 2025
General Payments
$383.82
19 reported records · 10 companies
Healthcare provider profile · identity verified
Elizabeth G Mathison, MD
Allopathic & Osteopathic Physicians|Family Medicine · MOBILE, AL · NPI 1750398434
Verified facts
What the public records show
CMS Open Payments records show Elizabeth G Mathison, MD received $383.82 in general payments during 2025 across 19 reported records.
SANOFI-AVENTIS U.S. LLC accounted for 18.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Ozempic by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $71.79 | 18.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $70.14 | 18.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $57.64 | 15.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $49.58 | 12.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.60 | 7.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $25.76 | 6.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.39 | 5.8% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $22.30 | 5.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.72 | 4.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.90 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $383.82 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $71.79 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $54.00 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $25.76 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $24.80 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.80 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $22.30 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 37 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 64 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
64 | 15 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 504 | 151 |
| Atorvastatin Calcium | Atorvastatin Calcium | 398 | 118 |
| Levothyroxine Sodium | Levothyroxine Sodium | 375 | 110 |
| Lisinopril | Lisinopril | 324 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 303 | 99 |
| Losartan Potassium | Losartan Potassium | 284 | 85 |
| Pravastatin Sodium | Pravastatin Sodium | 270 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 270 | 83 |
| Metformin Hcl | Metformin Hcl | 256 | 82 |
| Hydrochlorothiazide | Hydrochlorothiazide | 237 | 73 |
| Gabapentin | Gabapentin | 220 | 66 |
| Trazodone Hcl | Trazodone Hcl | 183 | 59 |
| Famotidine | Famotidine | 180 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 173 | 50 |
| Simvastatin | Simvastatin | 169 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 150 | 30 |
| Clonazepam | Clonazepam | 143 | 27 |
| Omeprazole | Omeprazole | 140 | 40 |
| Potassium Chloride | Potassium Chloride | 140 | 48 |
| Tramadol Hcl | Tramadol Hcl | 137 | 34 |
| Alprazolam | Alprazolam | 129 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 30 |
| Ezetimibe | Ezetimibe | 118 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 109 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 99 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 96 | 26 |
| Bupropion Xl | Bupropion Hcl | 95 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 25 |
| Montelukast Sodium | Montelukast Sodium | 87 | 36 |
| Sertraline Hcl | Sertraline Hcl | 85 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 81 | 29 |
| Furosemide | Furosemide | 80 | 30 |
| Atenolol | Atenolol | 76 | 18 |
| Allopurinol | Allopurinol | 75 | 21 |
| Meloxicam | Meloxicam | 75 | 28 |
| Metformin Hcl Er | Metformin Hcl | 69 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 69 | 19 |
| Ozempic | Semaglutide | 64 | 15 |
| Clonidine Hcl | Clonidine Hcl | 62 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 59 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 54 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 23 |
| Donepezil Hcl | Donepezil Hcl | 50 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 47 | suppressed |
| Synthroid | Levothyroxine Sodium | 47 | 13 |
| Lorazepam | Lorazepam | 46 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 14 |
| Fenofibrate | Fenofibrate,micronized | 42 | 12 |
| Buspirone Hcl | Buspirone Hcl | 41 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 41 | 12 |
| Pregabalin | Pregabalin | 41 | 14 |
| Carvedilol | Carvedilol | 40 | 11 |
| Glimepiride | Glimepiride | 39 | 11 |
| Jardiance | Empagliflozin | 37 | 11 |
| Valacyclovir | Valacyclovir Hcl | 37 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | 11 |
| Valsartan | Valsartan | 34 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 14 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 31 | suppressed |
| Temazepam | Temazepam | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 23 |
| Azithromycin | Azithromycin | 25 | 23 |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | 11 |
| Estradiol | Estradiol | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | 11 |
| Cephalexin | Cephalexin | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 14 |
| Vyvanse | Lisdexamfetamine Dimesylate | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 12 |
| Eliquis | Apixaban | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $383.82 · 19 records | SANOFI-AVENTIS U.S. LLC | AREXVY, Cologuard Collection Kit, FARXIGA, JARDIANCE, KISUNLA, Kerendia, LOREEV XR, MOUNJARO, Ozempic, QULIPTA, REXULTI, Rybelsus, SHINGRIX, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error